Get the content you want anytime you want.
REGISTER NOW | SIGN IN
The Best Infectious Disease News Delivered Weekly

The Contagion® Blood-borne specialty page provides blood-borne-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

BLOOD-BORNE DISEASES NEWS - Page 7

Age is No Longer a Barrier to Hepatitis C Treatment with Newer DAAs
A recent study finds that the use of sofosbuvir-based direct-acting antivirals for HCV treatment was effective and well-tolerated in elderly patients.
Hepatitis B Vaccine Continues to Jump Hurdles on Its Way to Potential FDA Approval
The decision date for a NDA for a new hepatitis B vaccine, Dynavax’s Heplisav-B, has been delayed, as the FDA asked for more post-marketing study information on the vaccine.
Risk for Cancer-Causing Infections Highest in Low- and Middle-Income Countries
Despite the progress that has been made, more research is needed on cancer prevention, hepatitis B, and human papillomavirus vaccines.
Treatment as Prevention: A Comprehensive Approach to Hepatitis C Virus in Persons Who Inject Drugs
With IV drug use accounting for 60% of new infections, treatment for individuals in this population is necessary to stave off new infections.
Top 5 <i>Contagion</i>® News Articles for the Week of July 30, 2017
New HIV drugs, vaccine regulations in France, correlations between intestinal viruses & type 1 diabetes, the susceptibility of Florida mosquitoes to transmit chikungunya, and an evaluation of the risk of hepatitis B reactivation in veterans on direct-acting antiviral therapy make up our Top 5 articles for the week of July 30, 2017.
Mavyret Approved for Patients with Chronic HCV Genotypes 1-6 Without Cirrhosis
The US Food and Drug Administration approved Mavyret for adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis or with mild cirrhosis.
HBV Reactivation More Severe in HBV/HCV Coinfected Patients Receiving DAA Therapy
A recent study finds that HBV reactivation occurs earlier and is more severe in HBV/HCV coinfected patients treated with DAA therapy compared with patients treated with IFN-based therapy.
FDA Advisory Committee Vote in Favor of Dynavax's Hepatitis B Vaccine
In a 12-1 vote, the FDA’s Vaccines and Related Biological Products Advisory Committee supported the safety data of a new potential hepatitis B vaccine.
FEATURED
We break down our top HIV news stories of 2017. Did you read them all?
x